Protective effects of ferulic acid in amyloid precursor protein plus presenilin-1 transgenic mouse model of Alzheimer disease.
We previously reported the protective effects of long-term administration of ferulic acid against the in vivo toxicity of β-amyloid peptide administered intracerebroventricularly in mice. In the present study, we investigated the effects of ferulic acid in transgenic amyloid precursor protein (APP)swe/presenilin 1 (PS1)dE9 (APP/PS1) mouse model of Alzheimer disease (AD). Chronic (for 6 months from the age of 6 to 12 months) oral administration of ferulic acid at a dose of 5.3 mg/kg/day significantly enhanced the performance in novel-object recognition task, and reduced amyloid deposition and interleukin-1 beta (IL-1β) levels in the frontal cortex. These results suggest that ferulic acid at a certain dosage could be useful for prevention and treatment of AD.
Department of Pharmacology, College of Medicine, Institute of Natural Medicine, IDMRC, Hallym University, Chuncheon 200–702, Republic of Korea.
Ji-Jing
JJ
Yan
Jun-Sub
JS
Jung
Taek-Keun
TK
Kim
Ashraful
A
Hasan
Chang-Won
CW
Hong
Ju-Suk
JS
Nam
Dong-Keun
DK
Song
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D016229:Amyloid beta-Peptides / Q000378:metabolism; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D003373:Coumaric Acids / Q000627:therapeutic use*; D005260:Female; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism; D053583:Interleukin-1beta / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D053764:Presenilin-1 / Q000235:genetics; D021641:Recognition, Psychology / Q000187:drug effects
D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D003373:Coumaric Acids; D053583:Interleukin-1beta; D018696:Neuroprotective Agents; D053764:Presenilin-1; C004999:ferulic acid